Capital Insight Partners’s GSK GSK Stock Holding History

Capital Insight Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25,782	Closed	-$1.3M	–	81
2018 Q2	$1.3M	Buy	25,782 +708	+3%	+$35.7K	1.07%	44
2018 Q1	$1.23M	Buy	25,074 +2,856	+13%	+$133K	1%	48
2017 Q4	$985K	Sell	22,218 -2,605	-10%	-$120K	0.77%	58
2017 Q3	$1.26M	Sell	24,823 -20,539	-45%	-$1.04M	1.06%	48
2017 Q2	$2.44M	Sell	45,362 -1,696	-4%	-$90.4K	2.17%	17
2017 Q1	$2.48M	Buy	47,058 +15,497	+49%	+$786K	2.25%	14
2016 Q4	$1.52M	Sell	31,561 -12,489	-28%	-$617K	1.51%	31
2016 Q3	$2.38M	Sell	44,050 -3,812	-8%	-$209K	2.28%	19
2016 Q2	$2.59M	Sell	47,862 -787	-2%	-$41.5K	2.46%	16
2016 Q1	$2.47M	Buy	48,649 +643	+1%	+$32K	2.51%	17
2015 Q4	$2.42M	Buy	48,006 +8,816	+22%	+$449K	2.45%	17
2015 Q3	$1.88M	Buy	39,190 +5,653	+17%	+$294K	1.77%	31
2015 Q2	$1.75M	Buy	+33,537	New	+$1.89M	1.48%	36

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Capital Insight Partners's GSK Position: Q3 2018 in Review

Capital Insight Partners sold out of GSK (GSK) in Q3 2018, closing a stake of 25,782 shares — an estimated $1.3M sold.

Capital Insight Partners first reported a position in GSK in Q2 2015 and held it in 13 quarters. The position peaked at $2.59M in Q2 2016. 788 funds tracked by Wall St. Rank hold GSK as of Q3 2018.

Capital Insight Partners reported no remaining GSK position as of Q3 2018 after selling out during the quarter.
Capital Insight Partners sold 25,782 GSK shares in Q3 2018, an estimated $1.3M.
Capital Insight Partners first reported a position in GSK in Q2 2015 and held it in 13 quarters.
Capital Insight Partners's GSK position peaked at $2.59M in Q2 2016.
788 funds tracked by Wall St. Rank held GSK as of Q3 2018.

Based on Capital Insight Partners's 13F filing for Q3 2018, filed 4 Oct 2018.